Of note, ~69% (9 of 13 cases) with RD were ER-positive, consistent with other studies where has been observed rates of pCR in neoadjuvant treated HER2+ breast cancer are lower in patients with ER-positive tumours5,7,11,17. This evidence concerns the gene ESR1 and breast carcinoma.